ProCE Banner Activity

Tebentafusp ± Durvalumab and/or Tremelimumab in Metastatic Cutaneous Melanoma: Updated OS Analysis From IMCgp100-201 Trial

Slideset Download
Conference Coverage
In this updated analysis of patients with PD-/PD-L1–treated metastatic cutaneous melanoma, tebentafusp, a bispecific therapy targeting gp100 and CD3, plus anti–PD-L1 was associated with a promising 1-year OS rate of 75%.

Released: June 13, 2022

Expiration: June 12, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab